Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Clinical Cancer Research|2025Cited by 12
Outcomes and endpoints of relevance in gynecologic cancer clinical trialsAinhoa Madariaga, Antonio González-Martı́n, Rodrigo Sánchez-Bayona et al.|International Journal of Gynecological Cancer|2023Cited by 11
LBA32 Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinomaSusana Banerjee, George Coukos, Apostolos Sarivalasis et al.|Annals of Oncology|2021Cited by 4
Data from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II StudySusana Banerjee, George Coukos, Eleonora Ghisoni et al.|Unknown|2025Cited by 0